Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of 14 systematic review(s)/meta-analysis(es). ^[1-14]
• Reduction in Relapse Rates and Disability Progression: Ocrelizumab demonstrated a significant reduction in annualized relapse rates (ARR) and disability progression in both relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). It was superior in controlling disease progression, showing a large reduction in relapse rate and disability progression compared to interferon beta-1a at 96 weeks (moderate-certainty evidence).
• MRI Outcomes: Ocrelizumab reduced the number of participants with gadolinium-enhancing T1 lesions and new or enlarging T2-hyperintense lesions on MRI at 96 weeks in RMS, demonstrating its effectiveness in decreasing disease activity on imaging compared to interferon beta-1a (low-certainty evidence).
• Efficacy in Timed 25-Foot Walk (T25FW): Ocrelizumab also performed best in the timed 25-foot walk test, an important measure of physical function in patients with progressive multiple sclerosis, indicating its benefits in improving mobility (low-certainty evidence).
• Ocrelizumab was associated with a higher rate of adverse events compared to placebo in patients with primary progressive multiple sclerosis (PPMS), with moderate-certainty evidence indicating a slightly higher proportion of withdrawals due to adverse events. Common adverse events included infusion-related reactions, nasopharyngitis, urinary tract infections, and upper respiratory tract infections.
• Ocrelizumab was linked to decreasing IgG levels, which potentially increased the risk of serious infections over time. This risk was similar to that observed with other monoclonal antibodies, with a comparable rate of serious adverse events but a higher likelihood of common infections compared to other disease-modifying therapies (DMTs) like interferon beta-1a.